Table 1:
Baseline Patient Characteristics
| Escalation cohort (n=13) | Expansion cohort (n=22) | All patients (n=35) | |
|---|---|---|---|
| Median age (years) | 53 | 54 | 54 |
| Race/ethnicity | |||
| Asian | 1 (7.5%) | 2 (9%) | 3 (9%) |
| Black | 1 (7.5%) | 1 (5%) | 2 (6%) |
| White | 7 (54%) | 17 (77%) | 24 (69%) |
| Unknown | 4 (31%) | 2 (9%) | 6 (17%) |
| Hispanic | 0 | 1 (5%) | 1 (3%) |
| Prior lines of treatment in the metastatic setting (median) | 3 | 2 | 2 |
| Hormone therapy | 13 (100%) | 22 (100%) | 35 (100%) |
| Aromatase inhibitors or tamoxifen | 13 (100%) | 21 (95%) | 34 (97%) |
| Fulvestrant | 9 (69%) | 9 (41%) | 18 (51%) |
| GnRH agonists | 3 (23%) | 10 (45%) | 13 (37%) |
| CDK4/6 inhibitor | 13 (100%) | 22 (100%) | 35 (100%) |
| PI3K pathway inhibitor | 4 (31%) | 4 (18%) | 8 (23%) |
| Chemotherapy | 13 (100%) | 13 (59%) | 23 (66%) |
| Metastatic Sites | |||
| Bone | 13 (100%) | 15 (68%) | 28 (80%) |
| Brain | 2 (15%) | 0 | 2 (6%) |
| Liver | 12 (92%) | 8 (36%) | 20 (57%) |
| Lung | 6 (46%) | 7 (32%) | 13 (37%) |
| Lymph node | 3 (23%) | 6 (27%) | 9 (26%) |
| Pleural / peritoneal | 4 (31%) | 1 (5%) | 5 (14%) |
| FGFR gene alteration | |||
| FGFR1 amp | 9 (69%) | 20 (91%) | 29 (83%) |
| FGFR2 amp | 0 | 1 (5%) | 1 (3%) |
| FGFR3 amp | 0 | 1 (5%) | 1 (3%) |
| No FGFR1-4 amp | 4 (31%) | 2 (9%) | 6 (17%) |
Aromatase inhibitors include letrozole, anastrozole and exemestane. GnRH: Gonadotropin-releasing hormone agonists include leuprolide acetate and goserelin acetate.